Opinion of the Transparency Council – acidum folicum
At its meeting on 9 December 2024, the Transparency Council adopted opinion No. 200/2024 on the inclusion in reimbursement of medicines containing the active substance acidum folicum in the scope of indications for use or dosage or method of administration different from those specified in the Summary of Product Characteristics, i.e. rheumatic diseases – in patients treated with methotrexate